文献速递肿瘤 PET/CT

[18F]FDG-PET/CT总病灶糖酵解变化可准确识别皮肤鳞癌新辅助免疫治疗早期应答

[18F]FDG-PET/CT's change in total lesion glycolysis can accurately identify early response upon neoadjuvant immunotherapy prior to curative-intent surgery in cutaneous squamous cell carcinoma; MATISSE trial.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2025-10-28

MATISSE随机II期试验评估可切除皮肤鳞状细胞癌患者接受两周期新辅助纳武利尤单抗(±低剂量伊匹木单抗)后,序贯[18F]FDG-PET/CT作为应答生物标志物的可行性。42例可评估患者中31例(74%)达主要或部分缓解,ΔTLG50%与ΔTLG4.0与原发灶及索引淋巴结应答强相关,准确率分别达92%/96%和91%/89%。

要点

  • FDG-PET的TLG早期变化可准确识别新辅助免疫治疗应答者与非应答者。
  • EORTC标准低估应答但可准确识别非应答者(敏感度70%、特异度100%)。
  • 应答者原发灶与索引淋巴结的SUVmax、MTV、TLG中位值显著下降。

核心结论

  • 定量FDG-PET应答评估可在手术前早期识别局部晚期CSCC新辅助免疫治疗的应答者与非应答者。
  • FDG-PET的TLG早期变化可支持未来旨在安全降级当前标准手术(±辅助放疗)的试验。

研究设计与样本

  • MATISSE为随机II期试验,50例CSCC患者接受两周期新辅助纳武利尤单抗(第0、2周)±低剂量伊匹木单抗(第0周),第4周手术。
  • 治疗前及术前短期行FDG-PET,评估原发肿瘤与最大(索引)淋巴结转移的SUVmax、MTV、TLG变化。
  • ΔMTV50%/4.0与ΔTLG50%/4.0分别采用50% SUVmax阈值和SUV≥4.0阈值计算。

主要发现

  • 42例可评估患者中31例(74%)对免疫治疗达主要或部分缓解。
  • EORTC标准低估应答,但准确识别非应答者(敏感度70%、特异度100%)。
  • 28例原发肿瘤和22例索引淋巴结中,应答者较非应答者的中位SUVmax、MTV50%、MTV4.0、TLG50%、TLG4.0显著下降(原发灶总体p≤0.004,索引淋巴结p≤0.03)。
  • ΔTLG50%与ΔTLG4.0与应答强相关(原发灶准确率92%和96%;索引淋巴结91%和89%)。

关键数值与推荐

  • ΔTLG50%与原发灶应答准确率92%,索引淋巴结91%。
  • ΔTLG4.0与原发灶应答准确率96%,索引淋巴结89%。
  • EORTC标准识别非应答者敏感度70%、特异度100%。

临床怎么用

  • 对可切除局部晚期CSCC新辅助免疫治疗患者,可用序贯FDG-PET的TLG早期变化辅助识别应答状态。
  • EORTC标准可用于确认非应答者,但可能低估应答。

局限性

  • 原文未报告局限性相关内容。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Ultra-short immunotherapy may spare cutaneous squamous cell carcinoma (CSCC) patients from mutilating surgery, but early identification of (non-)response is needed to safely guide treatment adaptation. This study evaluated the feasibility of sequential [18F]FDG-PET/CT (FDG-PET) as a response biomarker in resectable CSCC patients. METHODS: In the MATISSE, a randomized phase-II trial, 50 CSCC patients received two courses of neoadjuvant nivolumab (weeks 0 and 2) with or without low-dose ipilimumab (week 0) before surgery (week 4). FDG-PET scans were obtained pre-treatment and shortly prior to surgery to assess the change (Δ) in maximum standardized uptake value (SUVmax), metabolic tumor volume (MTV), and total lesion glycolysis (TLG) at the primary tumour and largest (= index) lymph node metastasis (ILN). ΔMTV50%/4.0 and ΔTLG50%/4.0 were calculated using thresholds of 50% SUVmax and SUV ≥ 4.0. RESULTS: In 42 evaluable patients, 31 (74%) patients showed major or partial responses to immunotherapy. EORTC-criteria underestimated response but accurately identified non-responders (70% sensitivity, 100% specificity). In 28 primary tumours and 22 ILNs, a significant reduction in median SUVmax, MTV50%, MTV4.0, TLG50%, and TLG4.0 was observed in responders versus non-responders (overall, p ≤ 0.004, and p ≤ 0.03, respectively). ΔTLG50% and ΔTLG4.0 correlated strongly with response (primary: 92% and 96% accuracy; ILN: 91% and 89% accuracy). CONCLUSIONS: Quantitative FDG-PET-response assessment allows early identification of (non-)responders upon neoadjuvant immunotherapy prior to surgery in locoregionally advanced CSCC patients. Early changes in FDG-PET's TLG can support future trials aiming at safe de-escalation of current standard of care surgery with or without adjuvant radiotherapy. TRIAL REGISTRATION: EudraCT 2020-001074-30. Registered 9 March 2020, https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001074-30.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Breukers SE, Crommelin RD, Smit LA, et al. [18F]FDG-PET/CT's change in total lesion glycolysis can accurately identify early response upon neoadjuvant immunotherapy prior to curative-intent surgery in cutaneous squamous cell carcinoma; MATISSE trial. Eur J Nucl Med Mol Imaging. 2025. PMID: 41145919. doi:10.1007/s00259-025-07518-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。